Public-registry site landscape for NCT05267262, a Alport Syndrome study sponsored by River 3 Renal Corp.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05267262 (registry record) |
| Sponsor | River 3 Renal Corp. |
| Condition(s) | Alport Syndrome; Focal Segmental Glomerulosclerosis |
| Phase | PHASE2 |
| Listed sites | 22 |
| Site countries | United States, Belgium, France, Germany, Netherlands, United Kingdom |
Eichor generates a preliminary site-risk snapshot for NCT05267262 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →